A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancer

ClinicalTrials.gov Show glossary Search for terms Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Related documents

• Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors#1044906
• Efficacy and Safety Study of the Therapeutic Vaccine PEP223 in Prostate Cancer Patients#979585
• Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)#249689
• Study to Gather Information About the Use of Healthcare Services and the Way the Disease is Cared for in Canadian Patients With Prostate Gland Cancer Which Spread Throughout the Body#851948
• The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density.#9092